Heavy alcohol users, whose GI function and liver metabolism are both impaired
Exclusion criteria included studies on conditions other than PD, those that did not use NAC or GSH as the primary intervention, and those without a comparator group
Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial
Some practices lack the infrastructure for baseline metabolic screening, oversight of dose changes, and management of gastrointestinal side effects
You can also compare workflows in our semaglutide progress tracking guide and broader GLP-1 progress guide if you are weighing different tracking needs.
Specific symptoms documented included diarrhea, flatulence, nausea, and increased appetite